Search Result

Results for "

half-life

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADAMTS (1) Adrenergic Receptor (1) Akt (2) Antibiotic (3) Antifolate (1) Apelin Receptor (APJ) (1) Apoptosis (1) Bacterial (2) c-Myc (1) Calcium Channel (1) CD3 (3) DNA-PK (2) DNA/RNA Synthesis (3) Dopamine Receptor (1) Drug Metabolite (3) Endogenous Metabolite (3) Factor Xa (1) FGFR (1) GABA Receptor (1) GCGR (1) HBV (1) HCV (2) HCV Protease (2) HDAC (1) IFNAR (1) Isotope-Labeled Compounds (2) JAK (1) JNK (1) Keap1-Nrf2 (1) LPL Receptor (1) MDM-2/p53 (1) MMP (1) Orexin Receptor (OX Receptor) (1) Orthopoxvirus (1) Parasite (2) Phosphatase (1) PI3K (2) Potassium Channel (1) Prostaglandin Receptor (1) Proton Pump (1) RSV (1) SARS-CoV (6) Sodium Channel (1) γ-secretase (2)
By Research Areas:	Cancer (15) Cardiovascular Disease (7) Endocrinology (4) Infection (14) Inflammation/Immunology (12) Metabolic Disease (3) Neurological Disease (8)

By Targets:

5-HT Receptor (1)

ADAMTS (1)

Adrenergic Receptor (1)

Akt (2)

Antibiotic (3)

Antifolate (1)

Apelin Receptor (APJ) (1)

Apoptosis (1)

Bacterial (2)

c-Myc (1)

Calcium Channel (1)

CD3 (3)

DNA-PK (2)

DNA/RNA Synthesis (3)

Dopamine Receptor (1)

Drug Metabolite (3)

Endogenous Metabolite (3)

Factor Xa (1)

FGFR (1)

GABA Receptor (1)

GCGR (1)

HBV (1)

HCV (2)

HCV Protease (2)

HDAC (1)

IFNAR (1)

Isotope-Labeled Compounds (2)

JAK (1)

JNK (1)

Keap1-Nrf2 (1)

LPL Receptor (1)

MDM-2/p53 (1)

MMP (1)

Orexin Receptor (OX Receptor) (1)

Orthopoxvirus (1)

Parasite (2)

Phosphatase (1)

PI3K (2)

Potassium Channel (1)

Prostaglandin Receptor (1)

Proton Pump (1)

RSV (1)

SARS-CoV (6)

Sodium Channel (1)

γ-secretase (2)

By Research Areas:

Cancer (15)

Cardiovascular Disease (7)

Endocrinology (4)

Infection (14)

Inflammation/Immunology (12)

Metabolic Disease (3)

Neurological Disease (8)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134636

PAPA NONOate	Endogenous Metabolite	Endocrinology
PAPA NONOate is a NO donor with a NO release half-life of 77 min (22-25°C). PAPA NONOate may represent a potential research for impaired wound healing in diabetes by increasing the rate of collagen synthesis at the wound site .

HY-13859

Clevudine L-FMAU	HBV DNA/RNA Synthesis Orthopoxvirus	Infection
Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .

HY-144771

SARS-CoV-2-IN-14	SARS-CoV	Infection
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-P99478

Bifarcept

IFNAR Inflammation/Immunology

Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .

Bifarcept	IFNAR	Inflammation/Immunology
Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .

HY-144772

SARS-CoV-2-IN-15	SARS-CoV	Infection
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-144770

SARS-CoV-2-IN-13	SARS-CoV	Infection
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-10758

FXa-IN-1	Factor Xa	Cardiovascular Disease
FXa-IN-1 is a FXa inhibitor (IC₅₀: 3 nM, K_i: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .

HY-103501

SB-205384	GABA Receptor	Neurological Disease
SB-205384 is a GABAA receptor modulator. The primary effect of SB-205384 on GABAA-activated currents is a prolonged response decay half-life upon removal of the agonist .

HY-145362

S1P1 agonist 4

LPL Receptor Others

S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

S1P1 agonist 4	LPL Receptor	Others
S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

HY-137270

16,16-Dimethyl PGA2 16,16-Dimethyl prostaglandin A2; Di-M-PGA2	Endogenous Metabolite	Endocrinology Cancer
16,16-Dimethyl PGA2 is an orally active prostaglandin analog with a prolonged in vivo half-life. 16,16-Dimethyl PGA2 can be used to study hypertension .

HY-135842

Aspoxicillin	Bacterial Antibiotic	Infection
Aspoxicillin is a broad-spectrum antimicrobial agent against 68 isolates of Actinobacillus pleuropneumoniae with an MIC₉₀ value of <= 0.05 μg/ml. Aspoxicillin has a long half-life in mouse serum of 55 minutes .

HY-148571

TP0597850

MMP Inflammation/Immunology Cancer

TP0597850 is a selective inhibitor of MMP2 (IC₅₀=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t_1/2=265 min) .

TP0597850	MMP	Inflammation/Immunology Cancer
TP0597850 is a selective inhibitor of MMP2 (IC₅₀=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t_1/2=265 min) .

HY-14834

Budiodarone ATI-2042	Potassium Channel Sodium Channel Calcium Channel	Cardiovascular Disease
Budiodarone (ATI-2042) is an analogue of Amiodarone (HY-14187) with a half-life of 7 h. Budiodarone inhibits sodium, potassium, and calcium ion channels. Budiodarone is an antiarrhythmic agent and can be used for the research of atrial fibrillation .

HY-118561

Bermoprofen AD-1590	Others	Inflammation/Immunology
Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory agent. Bermoprofen has potent antipyretic activities with a short biological half-life. Bermoprofen is a potent antagonist of LPS-induced fever in rabbits .

HY-125301

Thymoctonan	Others	Inflammation/Immunology
Thymoctonan (THF-γ2) is the immunomodulatory octapeptide, thymic humoral factor γ2. Thymoctonan has the half-life less than 6 min at 37 °C in blood from human, rat and mouse .

HY-W394903

GS-829845	JAK Drug Metabolite	Cancer
GS-829845 is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life .

HY-P99671

Isecarosmab M-6495	ADAMTS	Inflammation/Immunology
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a K_D value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .

HY-N4009

Iriflophenone 2-O-α-rhamnoside	Others	Others
Iriflophenone 2-O-α-rhamnoside can be isolated from the leaves of Aquilaria sinensis. Iriflophenone 2-O-α-rhamnoside has a half-life value of 2.44 min in rats at the administration of 25 mg/kg .

HY-100607A

Landiolol hydrochloride ONO1101 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta-blocker (β1/β2 selectivity = 255:1, a half-life of 4 min)， acts as an adrenoceptor antagonist .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-N7122

Thymopentin
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-N7122A

Thymopentin acetate	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-124713

ML372	DNA/RNA Synthesis	Neurological Disease
ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .

HY-P99756

Nirsevimab MEDI8897	RSV	Infection
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an K_d value of 1.5 nM. Nirsevimab can be used for RSV research .

HY-156188

AChE-IN-41	Others	Others
AChE-IN-41 (Compound 2) is a compound of the Galantamine Memantine hybrid. AChE-IN-41 has the inhibition ability of cholinesterase. AChE-IN-41 shows higher plasma stability and comparable microsomal stability in vitro, while showing lower half-life and faster clearance in vivo .

HY-P99930

Efruxifermin	FGFR	Metabolic Disease
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease
Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .

HY-14466

GW 848687X	Prostaglandin Receptor	Endocrinology
GW 848687X is a selective, orally active prostaglandin EP1 receptor antagonist for the inhibition of inflammatory pain. The oral bioavailability of GW 848687X was 54% in rats and 53% in dogs. GW 848687X has a half-life of 2 hours and has inhibitory potential for both acute and chronic pain .

HY-B1118S

Secnidazole-d6 RP-14539-d₆; PM-185184-d₆	Parasite Antibiotic	Infection
Secnidazole-d₆ is the deuterium labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research[1].

HY-100658

Didesmethyl cariprazine	5-HT Receptor Dopamine Receptor	Neurological Disease
Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic agent candidate that exhibits high affinity for the D₃ and D₂ receptors, and moderate affinity for the 5-HT_1A receptor .

HY-155507

c-Myc inhibitor 11	c-Myc	Cancer
c-Myc inhibitor 11 (Compound 67e) is a c-MYC inhibitor (pEC₅₀: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .

HY-162351

EBP-IN-1	Others	Metabolic Disease
EBP-IN-1 (compound 11) is an inhibitor of emopamil-binding protein (EBP), a sterol isomerase in the cholesterol biosynthetic pathway. EBP-IN-1 has a long half-life in rodents and has good metabolic turnover and brain penetration properties. EBP-IN-1 enhances oligodendrocyte formation in human cortical organoids .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-121246

Fluorofenidone AKF-PD	PI3K Akt	Inflammation/Immunology
Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway .

HY-17421

Tenatoprazole TU-199	Proton Pump	Infection Inflammation/Immunology
Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H ⁺/K ⁺-ATPase activity with an IC₅₀ of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .

HY-B1118S1

Secnidazole-13C2, 15N2 RP-14539-¹³C₂, ¹⁵N₂; PM-185184-¹³C₂, ¹⁵N₂	Isotope-Labeled Compounds Parasite Antibiotic	Infection
Secnidazole- ¹³C₂, ¹⁵N₂ is the ¹³C₂, ¹⁵N₂ labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research.

HY-149014

OX2R-IN-1	Orexin Receptor (OX Receptor)	Neurological Disease
OX₂R-IN-1 (compound 15) is a low cytotoxicity profile OX₂R-IN-1 antagonist (a potential OX2R binder) with an IC₅₀ value of 484 μM. OX₂R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life .

HY-162121

Antitumor agent-129	Others	Cancer
Antitumor agent-129 (Compound 68) is a thiazolidin-4-one sulfone derivative and an Osteosarcoma (OS) inhibitor with an IC₅₀ value of 0.217 μM, a half-life of 73.8 min (mouse liver microsome) and an excellent pharmacokinetic profile (in vivo bioavailability F = 115%, intraperitoneal administration). Antitumor agent-129 is a potential candidate for OS research .

HY-132242

DL-Sulforaphane N-acetyl-L-cysteine SFN-NAC	HDAC Apoptosis	Cancer
DL-Sulforaphane N-acetyl-L-cysteine (SFN-NAC) is an orally active HDAC inhibitor and metabolite of sulforaphane (HY-13755) with longer half-life and better blood-brain barrier permeability. DL-Sulforaphane N-acetyl-L-cysteine activates autophagy-mediated downregulation of α-tubulin expression through the ERK pathway and can be used in cancer research .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

HY-135774

6-Hydroxybenzbromarone	Drug Metabolite Phosphatase	Cardiovascular Disease
6-Hydroxybenzbromarone is the major metabolite of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound. 6-Hydroxybenzbromarone is a protein Eyes Absent 3 (EYA3) inhibitor with an IC₅₀ value of 21.5 μM. 6-Hydroxybenzbromarone is an anti-angiogenic agent, has strong inhibitory effects on cell migration, tubulogenesis, and angiogenic sprouting .

HY-121246S

Fluorofenidone-d3 AKF-PD-d₃	Isotope-Labeled Compounds Akt PI3K	Inflammation/Immunology
Fluorofenidone-d₃ is deuterium labeled Fluorofenidone. Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway[1][2].

HY-147336

Desmethylazelastine	Drug Metabolite	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Desmethylazelastine is a main active metabolite of Azelastine that is oxidatively metabolized by the cytochrome P450 enzyme system with a protein binding rate of 97% and an elimination half-life of 54 hours. Azelastine is an orally active, selective and high-affinity histamine H1-receptor antagonist. Azelastine can be used in studies of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2 .

HY-P99340

Sotrovimab VIR 7831	SARS-CoV	Infection
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-152142

DN-1289	JNK	Neurological Disease
DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase (DLK; IC₅₀=17 nM) and leucine zipper-bearing kinase (LZK; IC₅₀=40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability .

HY-155974

MeOIstPyrd	MDM-2/p53	Cancer
MeOIstPyrd is an anti-skin cancer agent. MeOIstPyrd inhibits cell proliferation, migration, and spheroid formation by activating the mitochondrial intrinsic apoptotic pathway. MeOIstPyrd induces DNA damage. MeOIstPyrd activates p53, and increases the half-life of p53 and stabilizes p53 by phosphorylating it at ser15. MeOIstPyrd binds to MDM2 in the p53 sub-pocket and blocks p53-MDM2 interaction .

HY-117482

BPN-15606	γ-secretase	Neurological Disease
BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC₅₀ values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance .

HY-117482A

BPN-15606 besylate	γ-secretase	Neurological Disease
BPN-15606 besylate is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC₅₀ values of 7 nM and 17nM, respectively. BPN-15606 besylate lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 besylate has acceptable PK/PD properties, including bioavailability, half-life, and clearance .

HY-P3347

NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal)	Apelin Receptor (APJ)	Cardiovascular Disease
NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) (compound 40), a macrocyclic analogue of Ape13, is a potent APJ agonist (K_i=5.7 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) exhibits a favorable Gα12-biased signaling and an increased in vivo half-life .

HY-12594

Paritaprevir 10+ Cited Publications ABT-450; Veruprevir	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

Cat. No.	Product Name	Target	Research Area